An Information Portal to 110790 Biological Macromolecular Structures

TXL is found in 2 entries
  •   Chemical Component Summary   Hide
    Identifiers (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
    Formula C43 H53 N O14
    Molecular Weight 807.88 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01248   (Stereoisomeric match)
    Name Docetaxel
    • approved
    • investigational
    Description Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.
    • Docetaxel anhydrous
    • N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
    • N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
    • TXL
    Brand names
    • Docefrez
    • Docetaxel
    • Taxotere
    Affected organism Humans and other mammals
    Indication For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
    Pharmacology Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
    Mechanism of action Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.
    Route of administration
    • intravenous
    Categories Antineoplastic Agents
    ATC-Code L01CD02
    AHFS-Code 10:00.00
    CAS number 114977-28-5
    Name Sequence search Pharmacological action Actions
    Tubulin beta-1 chain   Search  yes
    Apoptosis regulator Bcl-2   Search  unknown
    Nuclear receptor subfamily 1 group I member 2   Search  unknown binder
    Microtubule-associated protein 2   Search  yes
    Microtubule-associated protein tau   Search  yes
Ligand Image